{"transactions":[{"id":1875898,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-05-26T16:38:02.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of:  (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2024 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":24000,"derivative":{"exercise_price":1,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-23-032571","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000120919123032571/doc4.xml","form_type":"4"}},{"id":2221263,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-27T20:14:41.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2023 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":1.34,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-22-013392","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761922013392/doc1.xml","form_type":"4"}},{"id":2223806,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T20:13:39.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over one (1) year, with one hundred per cent (100%) of the award vesting on the first anniversary of the date of grant subject to the reporting person's continuous service through the vesting date."}],"balance_after":3500,"derivative":{"exercise_price":2.08,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001179110-22-003378","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000117911022003378/edgar.xml","form_type":"4"}},{"id":2250865,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-05-31T16:33:38.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of:  (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":24000,"derivative":{"exercise_price":1.76,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-22-032839","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000120919122032839/doc4.xml","form_type":"4"}},{"id":2283810,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-03T21:49:06.000Z","date":"2022-04-29","kind":"purchase","acquired":true,"shares":2118644,"price":2.36,"value":4999999.84,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired pursuant to a Securities Purchase Agreement dated April 26, 2022 between the Issuer, Versant Vantage II, L.P. (\"Vantage II\") and certain other investors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by Vantage II. Versant Vantage II GP, L.P. (\"Vantage II GP\") is the general partner of Vantage II, and Versant Vantage II GP-GP, LLC (\"Vantage II GP-GP\") is the general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":2118644,"source":{"system":"sec-edgar","filing":"0000899243-22-016387","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000089924322016387/doc4.xml","form_type":"4"}},{"id":2563802,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-21T00:13:06.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":6635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over three (3) years, with one-third (1/3) of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date."}],"balance_after":6635,"derivative":{"exercise_price":11.07,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":6635},"source":{"system":"sec-edgar","filing":"0001179110-21-008867","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000117911021008867/edgar.xml","form_type":"4/A","original_submission_date":"2021-07-06"}},{"id":2587693,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-27T17:49:26.000Z","date":"2021-08-25","kind":"other","acquired":true,"shares":128,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV I GP-GP."}],"balance_after":128,"source":{"system":"sec-edgar","filing":"0000899243-21-034443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000089924321034443/doc4.xml","form_type":"4"}},{"id":2587692,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-27T17:49:26.000Z","date":"2021-08-25","kind":"other","acquired":false,"shares":6612,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP-GP, to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held by VV I GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-034443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000089924321034443/doc4.xml","form_type":"4"}},{"id":2587691,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-27T17:49:26.000Z","date":"2021-08-25","kind":"other","acquired":true,"shares":6612,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Represents a change in the form of ownership of VV I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV I GP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held by VV I GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":6612,"source":{"system":"sec-edgar","filing":"0000899243-21-034443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000089924321034443/doc4.xml","form_type":"4"}},{"id":2587690,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-27T17:49:26.000Z","date":"2021-08-25","kind":"other","acquired":false,"shares":6668,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP, to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-034443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000089924321034443/doc4.xml","form_type":"4"}},{"id":2587689,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-27T17:49:26.000Z","date":"2021-08-25","kind":"other","acquired":true,"shares":6668,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a change in the form of ownership of VV I GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV I."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":6668,"source":{"system":"sec-edgar","filing":"0000899243-21-034443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000089924321034443/doc4.xml","form_type":"4"}},{"id":2587688,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-27T17:49:26.000Z","date":"2021-08-25","kind":"other","acquired":false,"shares":444744,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. (\"VV I\") to its partners pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Versant Vantage I, L.P. (\"VV I\"). Versant Vantage I GP-GP, LLC (\"VV I GP-GP\") is the sole general partner of Versant Vantage I GP, L.P. (\"VV I GP\") and VV I GP is the sole general partner of VV I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP, and the Reporting Person disclaims beneficial ownership of the shares held by VVI, except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":902965,"source":{"system":"sec-edgar","filing":"0000899243-21-034443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000089924321034443/doc4.xml","form_type":"4"}},{"id":2640534,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-06T22:01:21.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":6635,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service."}],"balance_after":6635,"derivative":{"exercise_price":11.07,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":6635},"source":{"system":"sec-edgar","filing":"0001140361-21-023542","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121023542/form4.xml","form_type":"4"}},{"id":2651254,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-06-30T01:54:43.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":7377,"ownership":{"direct":false,"nature":"By Versant Side Fund IV, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"This amount includes 1,897 shares that were acquired upon conversion of 58,927 shares of Tempest, which VSF IV agreed to purchase at a purchase price of $0.85 per share pursuant to a Funding Agreement with Tempest, which was conditioned upon the satisfaction or waiver of the conditions to Closing."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These shares are held of record by Versant Side Fund IV, L.P. (\"VSF IV\"). VV IV is the general partner of VSF IV. The Reporting Person is a managing member of VV IV and may be deemed to share voting and dispositive power over the shares held by VSF IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held of record by Versant Side Fund IV, L.P. (\"VSF IV\"). VV IV is the general partner of VSF IV. The Reporting Person is a managing member of VV IV and may be deemed to share voting and dispositive power over the shares held by VSF IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":7377,"source":{"system":"sec-edgar","filing":"0001140361-21-022782","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121022782/form4.xml","form_type":"4"}},{"id":2651253,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-06-30T01:54:43.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":1171094,"ownership":{"direct":false,"nature":"By Versant Venture Capital IV, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"This amount includes 301,161 shares that were acquired upon conversion of 9,352,838 shares of Tempest, which VVC IV agreed to purchase at a purchase price of $0.85 per share pursuant to a Funding Agreement with Tempest, which was conditioned upon the satisfaction or waiver of the conditions to Closing."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are held of record by Versant Venture Capital IV, L.P. (\"VVC IV\"). Versant Ventures IV, LLC (\"VV IV\") is the general partner of VVC IV. The Reporting Person is a managing member of VV IV and may be deemed to share voting and dispositive power over the shares held by VVC IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held of record by Versant Venture Capital IV, L.P. (\"VVC IV\"). Versant Ventures IV, LLC (\"VV IV\") is the general partner of VVC IV. The Reporting Person is a managing member of VV IV and may be deemed to share voting and dispositive power over the shares held by VVC IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":1171094,"source":{"system":"sec-edgar","filing":"0001140361-21-022782","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121022782/form4.xml","form_type":"4"}},{"id":2651252,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-06-30T01:54:43.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":997940,"ownership":{"direct":false,"nature":"By Versant Venture Capital VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held of record held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the general partner of VV VI GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VVC VI.  The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the general partner of VV VI GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VVC VI.  The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":997940,"source":{"system":"sec-edgar","filing":"0001140361-21-022782","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121022782/form4.xml","form_type":"4"}},{"id":2664038,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-17T21:14:57.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":26.58,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-21-012339","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761921012339/doc1.xml","form_type":"4"}},{"id":2668586,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T20:43:52.000Z","date":"2021-06-11","kind":"other","acquired":true,"shares":2226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV VI GP-GP."}],"balance_after":4452,"source":{"system":"sec-edgar","filing":"0000899243-21-023881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000089924321023881/doc4.xml","form_type":"4"}},{"id":2668585,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T20:43:52.000Z","date":"2021-06-11","kind":"other","acquired":false,"shares":8383,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV VI GP-GP, to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held by VV VI GP-GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held VV VI GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-023881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000089924321023881/doc4.xml","form_type":"4"}},{"id":2668584,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T20:43:52.000Z","date":"2021-06-11","kind":"other","acquired":true,"shares":8383,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Represents a change in the form of ownership of VV VI GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV VI GP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held by VV VI GP-GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held VV VI GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":8383,"source":{"system":"sec-edgar","filing":"0000899243-21-023881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000089924321023881/doc4.xml","form_type":"4"}},{"id":2668583,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T20:43:52.000Z","date":"2021-06-11","kind":"other","acquired":false,"shares":9719,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV VI GP, to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by VV VI GP. VV VI GP-GP is the general partner of VV VI GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VV VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-023881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000089924321023881/doc4.xml","form_type":"4"}},{"id":2668582,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T20:43:52.000Z","date":"2021-06-11","kind":"other","acquired":true,"shares":9719,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a change in the form of ownership of VV VI GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VVC VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by VV VI GP. VV VI GP-GP is the general partner of VV VI GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VV VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":9719,"source":{"system":"sec-edgar","filing":"0000899243-21-023881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000089924321023881/doc4.xml","form_type":"4"}},{"id":2668581,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T20:43:52.000Z","date":"2021-06-11","kind":"other","acquired":false,"shares":485979,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VI, L.P. (\"VVC VI\") to its partners pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by VVC VI. Versant Ventures VI GP, L.P. (\"VV VI GP\") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the general partner of VV VI GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VVC VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":1457937,"source":{"system":"sec-edgar","filing":"0000899243-21-023881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000089924321023881/doc4.xml","form_type":"4"}},{"id":2690637,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-05-28T18:06:09.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":16918,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":16918,"derivative":{"exercise_price":13.83,"expiration_date":"2031-05-26","underlying":"Common Stock","underlying_shares":16918},"source":{"system":"sec-edgar","filing":"0001209191-21-036630","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000120919121036630/doc4.xml","form_type":"4"}},{"id":2711959,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-14T20:05:38.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of May 12, 2022 or the 2022 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":3.7,"expiration_date":"2031-05-11","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-032964","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000120919121032964/doc4.xml","form_type":"4"}},{"id":2737355,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-28T21:00:46.000Z","date":"2021-04-26","kind":"other","acquired":true,"shares":2226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV VI GP-GP."}],"balance_after":2226,"source":{"system":"sec-edgar","filing":"0000899243-21-017187","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000089924321017187/doc4.xml","form_type":"4"}},{"id":2737354,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-28T21:00:46.000Z","date":"2021-04-26","kind":"other","acquired":false,"shares":8385,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV VI GP-GP, to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held by VV VI GP-GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held VV VI GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-017187","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000089924321017187/doc4.xml","form_type":"4"}},{"id":2737353,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-28T21:00:46.000Z","date":"2021-04-26","kind":"other","acquired":true,"shares":8385,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Represents a change in the form of ownership of VV VI GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV VI GP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held by VV VI GP-GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held VV VI GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":8385,"source":{"system":"sec-edgar","filing":"0000899243-21-017187","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000089924321017187/doc4.xml","form_type":"4"}},{"id":2737352,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-28T21:00:46.000Z","date":"2021-04-26","kind":"other","acquired":false,"shares":9720,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV VI GP, to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by VV VI GP. VV VI GP-GP is the general partner of VV VI GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VV VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-017187","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000089924321017187/doc4.xml","form_type":"4"}},{"id":2737351,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-28T21:00:46.000Z","date":"2021-04-26","kind":"other","acquired":true,"shares":9720,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a change in the form of ownership of VV VI GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VVC VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by VV VI GP. VV VI GP-GP is the general partner of VV VI GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VV VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":9720,"source":{"system":"sec-edgar","filing":"0000899243-21-017187","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000089924321017187/doc4.xml","form_type":"4"}},{"id":2737350,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-28T21:00:46.000Z","date":"2021-04-26","kind":"other","acquired":false,"shares":485979,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VI, L.P. (\"VVC VI\") to its partners pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by VVC VI. Versant Ventures VI GP, L.P. (\"VV VI GP\") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the general partner of VV VI GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VVC VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":1943916,"source":{"system":"sec-edgar","filing":"0000899243-21-017187","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000089924321017187/doc4.xml","form_type":"4"}},{"id":2924920,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-04T18:02:54.000Z","date":"2020-12-30","kind":"purchase","acquired":true,"shares":1347709,"price":3.71,"value":5000000.39,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by Versant Vantage I, L.P. (\"VV I\"). Versant Vantage I GP-GP, LLC (\"VV I GP-GP\") is the sole general partner of Versant Vantage I GP, L.P. (\"VV I GP\") and VV I GP is the sole general partner of VV I. The Reporting Person is a managing member of VV I GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1347709,"source":{"system":"sec-edgar","filing":"0000899243-21-000160","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000089924321000160/doc4.xml","form_type":"4"}},{"id":2941961,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-16T17:10:23.000Z","date":"2020-12-14","kind":"other","acquired":true,"shares":12783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures IV, LLC."}],"balance_after":18822,"source":{"system":"sec-edgar","filing":"0000899243-20-034129","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000089924320034129/doc4.xml","form_type":"4"}},{"id":3003119,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2020-10-20T21:00:09.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":198485,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Versant Vantage I, L.P. (\"VV I\"). Versant Vantage I GP, L.P. (\"VV I GP\") is the sole general partner of VV I. Versant Vantage I GP-GP, LLC (\"VV I GP-GP\") is the sole general partner of VV I GP and may be deemed to have voting and investment power over the securities held by VV I and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV I GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV I GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":198485},"source":{"system":"sec-edgar","filing":"0001567619-20-018012","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018012/doc1.xml","form_type":"4"}},{"id":3003118,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2020-10-20T21:00:09.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":85065,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the sole general partner of VVC VI. Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the sole general partner of VV VI GP and may be deemed to have voting and investment power over the securities held by VVC VI and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV VI GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV VI GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":85065},"source":{"system":"sec-edgar","filing":"0001567619-20-018012","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018012/doc1.xml","form_type":"4"}},{"id":3003117,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-10-20T21:00:09.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":463959,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Versant Vantage I, L.P. (\"VV I\"). Versant Vantage I GP, L.P. (\"VV I GP\") is the sole general partner of VV I. Versant Vantage I GP-GP, LLC (\"VV I GP-GP\") is the sole general partner of VV I GP and may be deemed to have voting and investment power over the securities held by VV I and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV I GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV I GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":463959},"source":{"system":"sec-edgar","filing":"0001567619-20-018012","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018012/doc1.xml","form_type":"4"}},{"id":3003116,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-10-20T21:00:09.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":198839,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the sole general partner of VVC VI. Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the sole general partner of VV VI GP and may be deemed to have voting and investment power over the securities held by VVC VI and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV VI GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV VI GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":198839},"source":{"system":"sec-edgar","filing":"0001567619-20-018012","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018012/doc1.xml","form_type":"4"}},{"id":3003115,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-10-20T21:00:09.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":2145991,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the sole general partner of VVC VI. Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the sole general partner of VV VI GP and may be deemed to have voting and investment power over the securities held by VVC VI and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV VI GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV VI GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2145991},"source":{"system":"sec-edgar","filing":"0001567619-20-018012","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018012/doc1.xml","form_type":"4"}},{"id":3003114,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T21:00:09.000Z","date":"2020-10-20","kind":"purchase","acquired":true,"shares":200000,"price":15,"value":3000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Versant Vantage I, L.P. (\"VV I\"). Versant Vantage I GP, L.P. (\"VV I GP\") is the sole general partner of VV I. Versant Vantage I GP-GP, LLC (\"VV I GP-GP\") is the sole general partner of VV I GP and may be deemed to have voting and investment power over the securities held by VV I and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV I GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV I GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":862444,"source":{"system":"sec-edgar","filing":"0001567619-20-018012","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018012/doc1.xml","form_type":"4"}},{"id":3003113,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T21:00:09.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":198485,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Versant Vantage I, L.P. (\"VV I\"). Versant Vantage I GP, L.P. (\"VV I GP\") is the sole general partner of VV I. Versant Vantage I GP-GP, LLC (\"VV I GP-GP\") is the sole general partner of VV I GP and may be deemed to have voting and investment power over the securities held by VV I and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV I GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV I GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":662444,"source":{"system":"sec-edgar","filing":"0001567619-20-018012","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018012/doc1.xml","form_type":"4"}},{"id":3003112,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T21:00:09.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":463959,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Versant Vantage I, L.P. (\"VV I\"). Versant Vantage I GP, L.P. (\"VV I GP\") is the sole general partner of VV I. Versant Vantage I GP-GP, LLC (\"VV I GP-GP\") is the sole general partner of VV I GP and may be deemed to have voting and investment power over the securities held by VV I and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV I GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV I GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":463959,"source":{"system":"sec-edgar","filing":"0001567619-20-018012","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018012/doc1.xml","form_type":"4"}},{"id":3003111,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T21:00:09.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":85065,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the sole general partner of VVC VI. Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the sole general partner of VV VI GP and may be deemed to have voting and investment power over the securities held by VVC VI and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV VI GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV VI GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2429895,"source":{"system":"sec-edgar","filing":"0001567619-20-018012","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018012/doc1.xml","form_type":"4"}},{"id":3003110,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T21:00:09.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":198839,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the sole general partner of VVC VI. Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the sole general partner of VV VI GP and may be deemed to have voting and investment power over the securities held by VVC VI and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV VI GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV VI GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2344830,"source":{"system":"sec-edgar","filing":"0001567619-20-018012","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018012/doc1.xml","form_type":"4"}},{"id":3003109,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T21:00:09.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":2145991,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the sole general partner of VVC VI. Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the sole general partner of VV VI GP and may be deemed to have voting and investment power over the securities held by VVC VI and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV VI GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV VI GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2145991,"source":{"system":"sec-edgar","filing":"0001567619-20-018012","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018012/doc1.xml","form_type":"4"}},{"id":3099581,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-25T17:45:56.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 23, 2021 or the 2021 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":30000,"derivative":{"exercise_price":25.64,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-038960","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000120919120038960/doc4.xml","form_type":"4"}},{"id":3102745,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-22T17:40:21.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":6.66,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001567619-20-012490","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000156761920012490/doc1.xml","form_type":"4"}},{"id":3233235,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75031,"kind":"organization","name":"Versant Vantage I, L.P.","position":4,"cik":"0001765253","reported_name":"Versant Vantage I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75032,"kind":"organization","name":"Versant Vantage I GP, L.P.","position":5,"cik":"0001777651","reported_name":"Versant Vantage I GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75033,"kind":"organization","name":"Versant Vantage I GP-GP, LLC","position":6,"cik":"0001777653","reported_name":"Versant Vantage I GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":113035,"kind":"person","name":"Woiwode Thomas","position":7,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-03T19:03:43.000Z","date":"2020-03-03","kind":"exercise","acquired":false,"shares":708352,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Vantage I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by by Versant Vantage I, L.P. (\"VV I\"). Versant Vantage I, GP, L.P. (\"VV I GP\") is the general partner of VV I, and Versant Vantage I, GP-GP, LLC (\"VV I GP-GP\") is the general partner of VV I GP. Each of Bradley J. Bolzon, Jerel C. Davis, Clare Ozawa, Robin L. Praeger and Thomas Woiwode Ph.D., as managing members of VV I GP-GP, may be deemed to share voting and dispositive power over the shares held by VV I and disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. A Form 4 is being filed separately by Dr. Woiwode in his capacity as a Director of the issuer."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":708352},"source":{"system":"sec-edgar","filing":"0001209191-20-015670","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1777651/000120919120015670/doc4.xml","form_type":"4"}},{"id":3233234,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75031,"kind":"organization","name":"Versant Vantage I, L.P.","position":4,"cik":"0001765253","reported_name":"Versant Vantage I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75032,"kind":"organization","name":"Versant Vantage I GP, L.P.","position":5,"cik":"0001777651","reported_name":"Versant Vantage I GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75033,"kind":"organization","name":"Versant Vantage I GP-GP, LLC","position":6,"cik":"0001777653","reported_name":"Versant Vantage I GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":113035,"kind":"person","name":"Woiwode Thomas","position":7,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2020-03-03T19:03:43.000Z","date":"2020-03-03","kind":"exercise","acquired":false,"shares":1049175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the general partner of VV VI GP. Each of Bradley J. Bolzon, Jerel C. Davis, Kirk G. Nielsen, Clare Ozawa, Robin L. Praeger and Tom Woiwode Ph.D., as managing members of VV VI GP-GP, may be deemed to share voting and dispositive power over the shares held by VVC VI and disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. A Form 4 is being filed separately by Dr. Woiwode in his capacity as a Director of the issuer."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1049175},"source":{"system":"sec-edgar","filing":"0001209191-20-015670","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1777651/000120919120015670/doc4.xml","form_type":"4"}},{"id":3233233,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75031,"kind":"organization","name":"Versant Vantage I, L.P.","position":4,"cik":"0001765253","reported_name":"Versant Vantage I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75032,"kind":"organization","name":"Versant Vantage I GP, L.P.","position":5,"cik":"0001777651","reported_name":"Versant Vantage I GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75033,"kind":"organization","name":"Versant Vantage I GP-GP, LLC","position":6,"cik":"0001777653","reported_name":"Versant Vantage I GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":113035,"kind":"person","name":"Woiwode Thomas","position":7,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2020-03-03T19:03:43.000Z","date":"2020-03-03","kind":"exercise","acquired":false,"shares":2977242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the general partner of VV VI GP. Each of Bradley J. Bolzon, Jerel C. Davis, Kirk G. Nielsen, Clare Ozawa, Robin L. Praeger and Tom Woiwode Ph.D., as managing members of VV VI GP-GP, may be deemed to share voting and dispositive power over the shares held by VVC VI and disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. A Form 4 is being filed separately by Dr. Woiwode in his capacity as a Director of the issuer."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2977242},"source":{"system":"sec-edgar","filing":"0001209191-20-015670","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1777651/000120919120015670/doc4.xml","form_type":"4"}},{"id":3233232,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75031,"kind":"organization","name":"Versant Vantage I, L.P.","position":4,"cik":"0001765253","reported_name":"Versant Vantage I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75032,"kind":"organization","name":"Versant Vantage I GP, L.P.","position":5,"cik":"0001777651","reported_name":"Versant Vantage I GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75033,"kind":"organization","name":"Versant Vantage I GP-GP, LLC","position":6,"cik":"0001777653","reported_name":"Versant Vantage I GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":113035,"kind":"person","name":"Woiwode Thomas","position":7,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T19:03:43.000Z","date":"2020-03-03","kind":"purchase","acquired":true,"shares":225000,"price":18,"value":4050000.0,"ownership":{"direct":false,"nature":"By Versant Vantage I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by by Versant Vantage I, L.P. (\"VV I\"). Versant Vantage I, GP, L.P. (\"VV I GP\") is the general partner of VV I, and Versant Vantage I, GP-GP, LLC (\"VV I GP-GP\") is the general partner of VV I GP. Each of Bradley J. Bolzon, Jerel C. Davis, Clare Ozawa, Robin L. Praeger and Thomas Woiwode Ph.D., as managing members of VV I GP-GP, may be deemed to share voting and dispositive power over the shares held by VV I and disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. A Form 4 is being filed separately by Dr. Woiwode in his capacity as a Director of the issuer."}],"balance_after":933352,"source":{"system":"sec-edgar","filing":"0001209191-20-015670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1777651/000120919120015670/doc4.xml","form_type":"4"}},{"id":3233231,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75031,"kind":"organization","name":"Versant Vantage I, L.P.","position":4,"cik":"0001765253","reported_name":"Versant Vantage I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75032,"kind":"organization","name":"Versant Vantage I GP, L.P.","position":5,"cik":"0001777651","reported_name":"Versant Vantage I GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75033,"kind":"organization","name":"Versant Vantage I GP-GP, LLC","position":6,"cik":"0001777653","reported_name":"Versant Vantage I GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":113035,"kind":"person","name":"Woiwode Thomas","position":7,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T19:03:43.000Z","date":"2020-03-03","kind":"exercise","acquired":true,"shares":708352,"ownership":{"direct":false,"nature":"By Versant Vantage I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by by Versant Vantage I, L.P. (\"VV I\"). Versant Vantage I, GP, L.P. (\"VV I GP\") is the general partner of VV I, and Versant Vantage I, GP-GP, LLC (\"VV I GP-GP\") is the general partner of VV I GP. Each of Bradley J. Bolzon, Jerel C. Davis, Clare Ozawa, Robin L. Praeger and Thomas Woiwode Ph.D., as managing members of VV I GP-GP, may be deemed to share voting and dispositive power over the shares held by VV I and disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. A Form 4 is being filed separately by Dr. Woiwode in his capacity as a Director of the issuer."}],"balance_after":708352,"source":{"system":"sec-edgar","filing":"0001209191-20-015670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777651/000120919120015670/doc4.xml","form_type":"4"}},{"id":3233230,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75031,"kind":"organization","name":"Versant Vantage I, L.P.","position":4,"cik":"0001765253","reported_name":"Versant Vantage I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75032,"kind":"organization","name":"Versant Vantage I GP, L.P.","position":5,"cik":"0001777651","reported_name":"Versant Vantage I GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75033,"kind":"organization","name":"Versant Vantage I GP-GP, LLC","position":6,"cik":"0001777653","reported_name":"Versant Vantage I GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":113035,"kind":"person","name":"Woiwode Thomas","position":7,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T19:03:43.000Z","date":"2020-03-03","kind":"exercise","acquired":true,"shares":1049175,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the general partner of VV VI GP. Each of Bradley J. Bolzon, Jerel C. Davis, Kirk G. Nielsen, Clare Ozawa, Robin L. Praeger and Tom Woiwode Ph.D., as managing members of VV VI GP-GP, may be deemed to share voting and dispositive power over the shares held by VVC VI and disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. A Form 4 is being filed separately by Dr. Woiwode in his capacity as a Director of the issuer."}],"balance_after":4026417,"source":{"system":"sec-edgar","filing":"0001209191-20-015670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777651/000120919120015670/doc4.xml","form_type":"4"}},{"id":3233229,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75031,"kind":"organization","name":"Versant Vantage I, L.P.","position":4,"cik":"0001765253","reported_name":"Versant Vantage I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75032,"kind":"organization","name":"Versant Vantage I GP, L.P.","position":5,"cik":"0001777651","reported_name":"Versant Vantage I GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75033,"kind":"organization","name":"Versant Vantage I GP-GP, LLC","position":6,"cik":"0001777653","reported_name":"Versant Vantage I GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":113035,"kind":"person","name":"Woiwode Thomas","position":7,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T19:03:43.000Z","date":"2020-03-03","kind":"exercise","acquired":true,"shares":2977242,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the general partner of VV VI GP. Each of Bradley J. Bolzon, Jerel C. Davis, Kirk G. Nielsen, Clare Ozawa, Robin L. Praeger and Tom Woiwode Ph.D., as managing members of VV VI GP-GP, may be deemed to share voting and dispositive power over the shares held by VVC VI and disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. A Form 4 is being filed separately by Dr. Woiwode in his capacity as a Director of the issuer."}],"balance_after":2977242,"source":{"system":"sec-edgar","filing":"0001209191-20-015670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777651/000120919120015670/doc4.xml","form_type":"4"}},{"id":3230621,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-03T18:57:12.000Z","date":"2020-03-03","kind":"exercise","acquired":false,"shares":708352,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Vantage I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Versant Vantage I, L.P. (\"VV I\"). Versant Vantage I GP, L.P. (\"VV I GP\") is the sole general partner of VV I. Versant Vantage I GP-GP, LLC (\"VV I GP-GP\") is the sole general partner of VV I GP and may be deemed to have voting and investment power over the securities held by VV I and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV I GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV I GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":708352},"source":{"system":"sec-edgar","filing":"0001209191-20-015661","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000120919120015661/doc4.xml","form_type":"4"}},{"id":3230620,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2020-03-03T18:57:12.000Z","date":"2020-03-03","kind":"exercise","acquired":false,"shares":1049175,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Venture Capital VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the sole general partner of VVC VI. Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the sole general partner of VV VI GP and may be deemed to have voting and investment power over the securities held by VVC VI and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV VI GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV VI GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1049175},"source":{"system":"sec-edgar","filing":"0001209191-20-015661","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000120919120015661/doc4.xml","form_type":"4"}},{"id":3230619,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2020-03-03T18:57:12.000Z","date":"2020-03-03","kind":"exercise","acquired":false,"shares":2977242,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Venture Capital VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the sole general partner of VVC VI. Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the sole general partner of VV VI GP and may be deemed to have voting and investment power over the securities held by VVC VI and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV VI GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV VI GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2977242},"source":{"system":"sec-edgar","filing":"0001209191-20-015661","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000120919120015661/doc4.xml","form_type":"4"}},{"id":3230618,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T18:57:12.000Z","date":"2020-03-03","kind":"purchase","acquired":true,"shares":225000,"price":18,"value":4050000.0,"ownership":{"direct":false,"nature":"By Versant Vantage I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Versant Vantage I, L.P. (\"VV I\"). Versant Vantage I GP, L.P. (\"VV I GP\") is the sole general partner of VV I. Versant Vantage I GP-GP, LLC (\"VV I GP-GP\") is the sole general partner of VV I GP and may be deemed to have voting and investment power over the securities held by VV I and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV I GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV I GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":933352,"source":{"system":"sec-edgar","filing":"0001209191-20-015661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000120919120015661/doc4.xml","form_type":"4"}},{"id":3230617,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T18:57:12.000Z","date":"2020-03-03","kind":"exercise","acquired":true,"shares":708352,"ownership":{"direct":false,"nature":"By Versant Vantage I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Versant Vantage I, L.P. (\"VV I\"). Versant Vantage I GP, L.P. (\"VV I GP\") is the sole general partner of VV I. Versant Vantage I GP-GP, LLC (\"VV I GP-GP\") is the sole general partner of VV I GP and may be deemed to have voting and investment power over the securities held by VV I and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV I GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV I GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":708352,"source":{"system":"sec-edgar","filing":"0001209191-20-015661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000120919120015661/doc4.xml","form_type":"4"}},{"id":3230616,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T18:57:12.000Z","date":"2020-03-03","kind":"exercise","acquired":true,"shares":1049175,"ownership":{"direct":false,"nature":"By Versant Venture Capital VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the sole general partner of VVC VI. Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the sole general partner of VV VI GP and may be deemed to have voting and investment power over the securities held by VVC VI and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV VI GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV VI GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":4026417,"source":{"system":"sec-edgar","filing":"0001209191-20-015661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000120919120015661/doc4.xml","form_type":"4"}},{"id":3230615,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T18:57:12.000Z","date":"2020-03-03","kind":"exercise","acquired":true,"shares":2977242,"ownership":{"direct":false,"nature":"By Versant Venture Capital VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the sole general partner of VVC VI. Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the sole general partner of VV VI GP and may be deemed to have voting and investment power over the securities held by VVC VI and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV VI GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV VI GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2977242,"source":{"system":"sec-edgar","filing":"0001209191-20-015661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000120919120015661/doc4.xml","form_type":"4"}},{"id":3237162,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-03-02T18:01:27.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":33836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 2.778% of the total shares monthly, commencing March 27, 2020, with 100% of the total shares vested on February 27, 2023, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":33836,"derivative":{"exercise_price":18,"expiration_date":"2030-02-27","underlying":"Common Stock","underlying_shares":33836},"source":{"system":"sec-edgar","filing":"0001209191-20-014702","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000120919120014702/doc4.xml","form_type":"4"}},{"id":3448784,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-02T16:25:08.000Z","date":"2019-07-31","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of (a) the 2020 annual meeting of stockholders and (b) July 31, 2020."}],"balance_after":45000,"derivative":{"exercise_price":13.41,"expiration_date":"2029-07-30","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-19-044254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000120919119044254/doc4.xml","form_type":"4"}},{"id":3482151,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-20T16:17:13.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":8570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date."}],"balance_after":8570,"derivative":{"exercise_price":10.86,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":8570},"source":{"system":"sec-edgar","filing":"0001567619-19-013764","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000156761919013764/doc1.xml","form_type":"4"}},{"id":3800524,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-10-02T17:29:34.000Z","date":"2018-10-02","kind":"exercise","acquired":false,"shares":929020,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Consists of (I) 815,302 shares held by Versant Venture Capital V, L.P. (\"VVC V\"), (ii) 62,048 shares held by Versant Venture Capital V (Canada) LP (\"VVC CAN\"), (iii) 27,146 shares held by Versant Ophthalmic Affiliates Fund I, L.P. (\"VOA\"), and (iv) 24,524 shares held by Versant Affiliates Fund V, L.P. (\"VAF V\"). Versant Ventures V, LLC, or VV V, serves as the sole general partner of VOA, VAF V and VVC V and owns no shares directly. Versant Ventures V (Canada) GP-GP, Inc. (\"VV V CAN GP\"), serves as the sole general partner of Versant Ventures V (Canada), L.P. (\"VV V CAN\"), which serves as the sole general partner of VVC CAN and owns no shares directly.The Reporting Person is a managing director of VV V and a director of VV V CAN GP and shares voting and dispositive power over the shares held by VOA, VAF V, VVC V and VVC CAN. He disclaims beneficial ownership of the shares held by VOA, VAF V, VVC V and VVC CAN, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":929020},"source":{"system":"sec-edgar","filing":"0001567619-18-003541","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000156761918003541/doc1.xml","form_type":"4"}},{"id":3800523,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2018-10-02T17:29:34.000Z","date":"2018-10-02","kind":"exercise","acquired":false,"shares":2173909,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Consists of (I) 1,907,729 shares held by Versant Venture Capital V, L.P. (\"VVC V\"), (ii) 145,186 shares held by Versant Venture Capital V (Canada) LP (\"VVC CAN\"), (iii) 63,610 shares held by Versant Ophthalmic Affiliates Fund I, L.P. (\"VOA\"), and (iv) 57,384 shares held by Versant Affiliates Fund V, L.P. (\"VAF V\"). Versant Ventures V, LLC, or VV V, serves as the sole general partner of VOA, VAF V and VVC V and owns no shares directly. Versant Ventures V (Canada) GP-GP, Inc. (\"VV V CAN GP\"), serves as the sole general partner of Versant Ventures V (Canada), L.P. (\"VV V CAN\"), which serves as the sole general partner of VVC CAN and owns no shares directly. The Reporting Person is a managing director of VV V and a director of VV V CAN GP and shares voting and dispositive power over the shares held by VOA, VAF V, VVC V and VVC CAN. He disclaims beneficial ownership of the shares held by VOA, VAF V, VVC V and VVC CAN, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2173909},"source":{"system":"sec-edgar","filing":"0001567619-18-003541","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000156761918003541/doc1.xml","form_type":"4"}},{"id":3800522,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T17:29:34.000Z","date":"2018-10-02","kind":"exercise","acquired":true,"shares":3102929,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of (I) 2,723,031 shares held by Versant Venture Capital V, L.P. (\"VVC V\"), (ii) 207,234 shares held by Versant Venture Capital V (Canada) LP (\"VVC CAN\"), (iii) 90.756 shares held by Versant Ophthalmic Affiliates Fund I, L.P. (\"VOA\"), and (iv) 81,908 shares held by Versant Affiliates Fund V, L.P. (\"VAF V\"). Versant Ventures V, LLC, or VV V,serves as the sole general partner of VOA, VAF V and VVC V and owns no shares directly. Versant Ventures V (Canada) GP-GP, Inc. (\"VV V CAN GP\"), serves as the sole general partner of Versant Ventures V (Canada), L.P. (\"VV V CAN\"), which serves as the sole general partner of VVC CAN and owns no shares directly. The Reporting Person is a managing director of VV V and a director of VV V CAN GP and shares voting and dispositive power over the shares held by VOA, VAF V, VVC V and VVC CAN. He disclaims beneficial ownership of the shares held by VOA, VAF V, VVC V and VVC CAN, except to the extent of his pecuniary interest therein."}],"balance_after":3102929,"source":{"system":"sec-edgar","filing":"0001567619-18-003541","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619294/000156761918003541/doc1.xml","form_type":"4"}},{"id":3892658,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-16T01:39:45.000Z","date":"2018-06-15","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Bradley Bolzon, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Bolzon. Each of the Reporting Person and Mr. Bolzon are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC."},{"field":"shares","element":"transactionShares","label":"F3","text":"(Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 15, 2018 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Bradley Bolzon, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Bolzon. Each of the Reporting Person and Mr. Bolzon are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"(Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Bradley Bolzon, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Bolzon. Each of the Reporting Person and Mr. Bolzon are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Bradley Bolzon, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Bolzon. Each of the Reporting Person and Mr. Bolzon are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":30000,"derivative":{"exercise_price":59.31,"expiration_date":"2028-06-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-18-016876","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318016876/doc4.xml","form_type":"4"}},{"id":3892140,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-15T16:27:26.000Z","date":"2018-05-31","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the one-year anniversary of May 31, 2018."}],"balance_after":35000,"derivative":{"exercise_price":6.25,"expiration_date":"2028-05-30","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-18-038055","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000120919118038055/doc4.xml","form_type":"4"}},{"id":3928372,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-17T21:11:57.000Z","date":"2018-05-15","kind":"sale","acquired":false,"shares":1000,"price":58.73,"value":58730.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.585 to $58.785  per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Venture Management, LLC (\"VVM LLC\"). The Reporting Person is a managing member of VVM LLC and may be deemed to indirectly beneficially own the shares through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein."}],"balance_after":640014,"source":{"system":"sec-edgar","filing":"0000899243-18-013239","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318013239/doc4.xml","form_type":"4"}},{"id":3928371,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-17T21:11:57.000Z","date":"2018-05-15","kind":"sale","acquired":false,"shares":43000,"price":57.97,"value":2492710.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.54 to $58.50  per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Venture Management, LLC (\"VVM LLC\"). The Reporting Person is a managing member of VVM LLC and may be deemed to indirectly beneficially own the shares through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein."}],"balance_after":641014,"source":{"system":"sec-edgar","filing":"0000899243-18-013239","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318013239/doc4.xml","form_type":"4"}},{"id":3941143,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-09T21:15:14.000Z","date":"2018-05-08","kind":"sale","acquired":false,"shares":1653,"price":51.45,"value":85046.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":5629,"source":{"system":"sec-edgar","filing":"0000899243-18-012101","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318012101/doc4.xml","form_type":"4"}},{"id":3941142,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-09T21:15:14.000Z","date":"2018-05-07","kind":"sale","acquired":false,"shares":582,"price":51.26,"value":29833.32,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P.\n(\"VVC CAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.61 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. (\"VV V CAN GP\") is the sole general partner of Versant Ventures V (Canada), L.P. (\"VV V CAN\") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":90730,"source":{"system":"sec-edgar","filing":"0000899243-18-012101","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318012101/doc4.xml","form_type":"4"}},{"id":3941141,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-09T21:15:14.000Z","date":"2018-05-07","kind":"sale","acquired":false,"shares":249,"price":51.26,"value":12763.74,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P.  (\"VOA\")."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.61 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":38772,"source":{"system":"sec-edgar","filing":"0000899243-18-012101","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318012101/doc4.xml","form_type":"4"}},{"id":3941140,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-09T21:15:14.000Z","date":"2018-05-07","kind":"sale","acquired":false,"shares":225,"price":51.26,"value":11533.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. (\"VAF V\")."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.61 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":34977,"source":{"system":"sec-edgar","filing":"0000899243-18-012101","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318012101/doc4.xml","form_type":"4"}},{"id":3941139,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-09T21:15:14.000Z","date":"2018-05-07","kind":"sale","acquired":false,"shares":7645,"price":51.26,"value":391882.7,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. (\"VVC V\")."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.61 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by VVC V. Versant Ventures V, LLC (\"VV V\") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1192139,"source":{"system":"sec-edgar","filing":"0000899243-18-012101","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318012101/doc4.xml","form_type":"4"}},{"id":3941138,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-09T21:15:14.000Z","date":"2018-05-07","kind":"sale","acquired":false,"shares":7424,"price":50.31,"value":373501.44,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P.\n(\"VVC CAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. (\"VV V CAN GP\") is the sole general partner of Versant Ventures V (Canada), L.P. (\"VV V CAN\") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":91312,"source":{"system":"sec-edgar","filing":"0000899243-18-012101","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318012101/doc4.xml","form_type":"4"}},{"id":3941137,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-09T21:15:14.000Z","date":"2018-05-07","kind":"sale","acquired":false,"shares":3172,"price":50.31,"value":159583.32,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P.  (\"VOA\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":39021,"source":{"system":"sec-edgar","filing":"0000899243-18-012101","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318012101/doc4.xml","form_type":"4"}},{"id":3941136,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-09T21:15:14.000Z","date":"2018-05-07","kind":"sale","acquired":false,"shares":2862,"price":50.31,"value":143987.22,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. (\"VAF V\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":35202,"source":{"system":"sec-edgar","filing":"0000899243-18-012101","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318012101/doc4.xml","form_type":"4"}},{"id":3941135,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-09T21:15:14.000Z","date":"2018-05-07","kind":"sale","acquired":false,"shares":97550,"price":50.31,"value":4907740.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. (\"VVC V\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by VVC V. Versant Ventures V, LLC (\"VV V\") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1199784,"source":{"system":"sec-edgar","filing":"0000899243-18-012101","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318012101/doc4.xml","form_type":"4"}},{"id":3949806,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-02T22:00:55.000Z","date":"2018-04-30","kind":"sale","acquired":false,"shares":2044,"price":50.29,"value":102792.76,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. (\"VVC CAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security h2older of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. (\"VV V CAN GP\") is the sole general partner of Versant Ventures V (Canada), L.P. (\"VV V CAN\") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":98736,"source":{"system":"sec-edgar","filing":"0000899243-18-011133","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318011133/doc4.xml","form_type":"4"}},{"id":3949805,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-02T22:00:55.000Z","date":"2018-04-30","kind":"sale","acquired":false,"shares":874,"price":50.26,"value":43927.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P.  (\"VOA\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security h2older of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":42193,"source":{"system":"sec-edgar","filing":"0000899243-18-011133","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318011133/doc4.xml","form_type":"4"}},{"id":3949804,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-02T22:00:55.000Z","date":"2018-04-30","kind":"sale","acquired":false,"shares":788,"price":50.29,"value":39628.52,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. (\"VAF V\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security h2older of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":38064,"source":{"system":"sec-edgar","filing":"0000899243-18-011133","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318011133/doc4.xml","form_type":"4"}},{"id":3949803,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-02T22:00:55.000Z","date":"2018-04-30","kind":"sale","acquired":false,"shares":26860,"price":50.29,"value":1350789.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. (\"VVC V\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security h2older of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by VVC V. Versant Ventures V, LLC (\"VV V\") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1297334,"source":{"system":"sec-edgar","filing":"0000899243-18-011133","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318011133/doc4.xml","form_type":"4"}},{"id":3953696,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-01T00:57:42.000Z","date":"2018-04-27","kind":"sale","acquired":false,"shares":779,"price":50.03,"value":38973.37,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. (\"VVC CAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.21 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. (\"VV V CAN GP\") is the sole general partner of Versant Ventures V (Canada), L.P. (\"VV V CAN\") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":100780,"source":{"system":"sec-edgar","filing":"0000899243-18-010983","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010983/doc4.xml","form_type":"4"}},{"id":3953695,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-01T00:57:42.000Z","date":"2018-04-27","kind":"sale","acquired":false,"shares":333,"price":50.01,"value":16653.33,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P.  (\"VOA\")."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.21 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":43067,"source":{"system":"sec-edgar","filing":"0000899243-18-010983","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010983/doc4.xml","form_type":"4"}},{"id":3953694,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-01T00:57:42.000Z","date":"2018-04-27","kind":"sale","acquired":false,"shares":300,"price":50.08,"value":15024.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. (\"VAF V\")."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.21 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":38852,"source":{"system":"sec-edgar","filing":"0000899243-18-010983","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010983/doc4.xml","form_type":"4"}},{"id":3953693,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-01T00:57:42.000Z","date":"2018-04-27","kind":"sale","acquired":false,"shares":10236,"price":50.02,"value":512004.72,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. (\"VVC V\")."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.21 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by VVC V. Versant Ventures V, LLC (\"VV V\") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1324194,"source":{"system":"sec-edgar","filing":"0000899243-18-010983","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010983/doc4.xml","form_type":"4"}},{"id":3953692,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-01T00:57:42.000Z","date":"2018-04-26","kind":"sale","acquired":false,"shares":14086,"price":50.11,"value":705849.46,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. (\"VVC CAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.45 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. (\"VV V CAN GP\") is the sole general partner of Versant Ventures V (Canada), L.P. (\"VV V CAN\") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":101559,"source":{"system":"sec-edgar","filing":"0000899243-18-010983","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010983/doc4.xml","form_type":"4"}},{"id":3953691,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-01T00:57:42.000Z","date":"2018-04-26","kind":"sale","acquired":false,"shares":6019,"price":50.12,"value":301672.28,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P.  (\"VOA\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.45 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":43400,"source":{"system":"sec-edgar","filing":"0000899243-18-010983","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010983/doc4.xml","form_type":"4"}},{"id":3953690,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-01T00:57:42.000Z","date":"2018-04-26","kind":"sale","acquired":false,"shares":5430,"price":50.12,"value":272151.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. (\"VAF V\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.45 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":39152,"source":{"system":"sec-edgar","filing":"0000899243-18-010983","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010983/doc4.xml","form_type":"4"}},{"id":3953689,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-01T00:57:42.000Z","date":"2018-04-26","kind":"sale","acquired":false,"shares":185075,"price":50.11,"value":9274108.25,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. (\"VVC V\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.45 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by VVC V. Versant Ventures V, LLC (\"VV V\") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1334430,"source":{"system":"sec-edgar","filing":"0000899243-18-010983","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010983/doc4.xml","form_type":"4"}},{"id":3956169,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-04-26T21:01:24.000Z","date":"2018-04-24","kind":"sale","acquired":false,"shares":1528,"price":51,"value":77928.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P.\n(\"VVC CAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. (\"VV V CAN GP\") is the sole general partner of Versant Ventures V (Canada), L.P. (\"VV V CAN\") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":115645,"source":{"system":"sec-edgar","filing":"0000899243-18-010841","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010841/doc4.xml","form_type":"4"}},{"id":3956168,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-04-26T21:01:24.000Z","date":"2018-04-24","kind":"sale","acquired":false,"shares":653,"price":51,"value":33303.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P.  (\"VOA\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":49419,"source":{"system":"sec-edgar","filing":"0000899243-18-010841","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010841/doc4.xml","form_type":"4"}},{"id":3956167,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-04-26T21:01:24.000Z","date":"2018-04-24","kind":"sale","acquired":false,"shares":589,"price":50.6,"value":29803.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. (\"VAF V\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":44582,"source":{"system":"sec-edgar","filing":"0000899243-18-010841","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010841/doc4.xml","form_type":"4"}},{"id":3956166,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-04-26T21:01:24.000Z","date":"2018-04-24","kind":"sale","acquired":false,"shares":20071,"price":51,"value":1023621.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. (\"VVC V\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.59 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by VVC V. Versant Ventures V, LLC (\"VV V\") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1519505,"source":{"system":"sec-edgar","filing":"0000899243-18-010841","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010841/doc4.xml","form_type":"4"}},{"id":3958055,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-04-24T23:42:19.000Z","date":"2018-04-23","kind":"sale","acquired":false,"shares":6821,"price":50.66,"value":345551.86,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F16","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P.\n(\"VVC CAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $54.00 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. (\"VV V CAN GP\") is the sole general partner of Versant Ventures V (Canada), L.P. (\"VV V CAN\") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":117173,"source":{"system":"sec-edgar","filing":"0000899243-18-010683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010683/doc4.xml","form_type":"4"}},{"id":3958054,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-04-24T23:42:19.000Z","date":"2018-04-23","kind":"sale","acquired":false,"shares":2915,"price":51,"value":148665.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F14","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P.  (\"VOA\")."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $54.00 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":50072,"source":{"system":"sec-edgar","filing":"0000899243-18-010683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010683/doc4.xml","form_type":"4"}},{"id":3958053,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-04-24T23:42:19.000Z","date":"2018-04-23","kind":"sale","acquired":false,"shares":2630,"price":51,"value":134130.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F12","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. (\"VAF V\")."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $54.00 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":45171,"source":{"system":"sec-edgar","filing":"0000899243-18-010683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010683/doc4.xml","form_type":"4"}},{"id":3958052,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-04-24T23:42:19.000Z","date":"2018-04-23","kind":"sale","acquired":false,"shares":89628,"price":50.66,"value":4540554.48,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ventures Capital V, L.P. (\"VVC V\")."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $54.00 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"These securities are held of record by VVC V. Versant Ventures V, LLC (\"VV V\") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1539576,"source":{"system":"sec-edgar","filing":"0000899243-18-010683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010683/doc4.xml","form_type":"4"}},{"id":3958051,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-04-24T23:42:19.000Z","date":"2018-04-20","kind":"other","acquired":true,"shares":2323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VV IV to its members."}],"balance_after":7282,"source":{"system":"sec-edgar","filing":"0000899243-18-010683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000089924318010683/doc4.xml","form_type":"4"}}],"next_cursor":"2018-04-24T23:42:19.000000Z,3958051"}